Oncology News

Pembrolizumab treatment led to durable OS and PFS among patients with advanced hepatocellular carcinoma who previously progressed on sorafenib, according to results of the phase 2 KEYNOTE-224 clinical trial presented at the Gastrointestinal Cancers Symposium.

Alcohol consumption in young men was associated with an increased, dose-dependent risk for severe liver disease up to 39 years later in life, according to results of a recently published study.

BETHESDA, Maryland — In this exclusive video from the AASLD Industry Colloquium 2018, Kris V. Kowdley, MD, FAASLD, from Swedish Medical Center in Seattle, Washington, discusses the topics covered at the meeting and the opportunities for representatives of the industry, academia and regulatory agencies to come together.

Exelixis and Ipsen announced results from the phase 3 Celestial trial of cabozantinib for hepatocellular carcinoma that showed significant overall survival benefit in patients previously treated for advanced HCC, according to a press release and data presented at the 2018 ASCO-GI Symposium in San Francisco.

Results of a comparative study of patients with and without diabetes who underwent curative liver resection for hepatitis C-related hepatocellular carcinoma showed that diabetes did not affect surgical outcomes and was not an unfavorable factor in selecting candidates.

Minimally invasive liver resection may be effective for patients with impaired liver function, as results from a recently published study showed that the procedure reduced blood loss and had lower complication rates that led to shorter hospital stays compared with open liver resection.

Regeneron has launched a consortium to fund the generation of genetic exome sequence data from 500,000 volunteer participants, the company announced in a press release.

Liver cancer rates continue to increase, prompting researchers to focus on leading causes such as hepatitis C and identifying major risk factors. Recent studies have identified some of these factors to include age, comorbidities and ethnicity.

Patients with hepatocellular carcinoma and clinically evident portal hypertension had significantly lower rates of complete response, progression free survival and overall survival after treatment with transarterial chemoembolization compared with those without portal hypertension, according to recently published data.

Researchers observed a low rate of complete response to sorafenib treatment for hepatocellular carcinoma in a recent retrospective study; however, nearly all patients who achieved complete response also developed dermatologic adverse events, which may provide a correlation between toxicity and treatment response.